Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more
Definium Therapeutics, Inc. (DFTX) - Total Assets
Latest total assets as of December 2025: $440.10 Million USD
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) holds total assets worth $440.10 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Definium Therapeutics, Inc. - Total Assets Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Definium Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Definium Therapeutics, Inc.'s total assets of $440.10 Million consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $19.92 Million | 4.5% |
Asset Composition Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Definium Therapeutics, Inc.'s current assets represent 95.3% of total assets in 2025, an increase from 63.9% in 2015.
- Cash Position: Cash and equivalents constituted 58.6% of total assets in 2025, up from 1.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 4.5% of total assets.
Definium Therapeutics, Inc. Competitors by Total Assets
Key competitors of Definium Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Definium Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Definium Therapeutics, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Definium Therapeutics, Inc. is currently not profitable relative to its asset base.
Definium Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.29 | 7.25 | 25.16 |
| Quick Ratio | 6.29 | 7.25 | 25.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $352.62 Million | $ 242.77 Million | $ 155.84 Million |
Definium Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Definium Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.72 |
| Latest Market Cap to Assets Ratio | 3.90 |
| Asset Growth Rate (YoY) | 45.7% |
| Total Assets | $440.10 Million |
| Market Capitalization | $1.72 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Definium Therapeutics, Inc.'s assets at a significant premium ( 3.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Definium Therapeutics, Inc.'s assets grew by 45.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual total assets of Definium Therapeutics, Inc. from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $440.10 Million | +45.66% |
| 2024-12-31 | $302.15 Million | +142.61% |
| 2023-12-31 | $124.54 Million | -26.74% |
| 2022-12-31 | $169.99 Million | +3.65% |
| 2021-12-31 | $164.00 Million | +101.18% |
| 2020-12-31 | $81.52 Million | +2675.66% |
| 2019-12-31 | $2.94 Million | -16.87% |
| 2018-12-31 | $3.53 Million | -12.28% |
| 2017-12-31 | $4.03 Million | +1886.43% |
| 2016-12-31 | $202.75K | -30.48% |
| 2015-12-31 | $291.66K | -- |